autologous CRISPR-edited tumor infiltrating lymphocytes GT316

A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from each patient's resected tumor and edited with the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system to eliminate the expression of as of yet not elucidated immunoregulatory targets, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, autologous CRISPR-edited TILs GT316 specifically recognize and kill the patient's tumor cells. The knockout of the immunoregulatory targets may enhance the proliferation and cytokine release of the TILs.